Literature DB >> 12406092

Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma.

Raman Desikan1, Yuliya Veksler, Syed Raza, Barry Stokes, Tariq Sabir, Zu Jun Li, Sundar Jagannath.   

Abstract

Five patients receiving increased dose or frequency of pamidronate beyond the recommended dose (90 mg/monthly) exhibited nephrotic proteinuria (range 3.96-24 g/24 h). On dose reduction or discontinuation, three of these patients showed decreased proteinuria to normal levels (< 1 g/24 h), and proteinuria decreased to 4.5 g/24 h from a peak of 24 g/24 h in one patient. One patient on haemodialysis (hence not evaluable) had proteinuria of 2 g/24 h and elevated creatinine levels. One other patient continued to show elevated creatinine levels (272.8 micro mol/l). Renal biopsies obtained in two patients revealed focal segmental glomerulosclerosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12406092     DOI: 10.1046/j.1365-2141.2002.03826.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

Review 1.  The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.

Authors:  Samantha Pozzi; Noopur Raje
Journal:  Oncologist       Date:  2011-04-14

2.  Pemetrexed induced acute kidney injury in patients with non-small cell lung cancer: reversible and chronic renal damage.

Authors:  Giuseppe Rombolà; Franco Vaira; Matteo Trezzi; Nadia Chiappini; Valeria Falqui; Francesco Londrino
Journal:  J Nephrol       Date:  2014-07-02       Impact factor: 3.902

3.  Alendronate associated focal segmental glomerulosclerosis: a case report and review of the literature.

Authors:  Pranav S Garimella; Helmut G Rennke; James A Strom
Journal:  CEN Case Rep       Date:  2015-04-01

4.  Nephrotic syndrome induced by pamidronate.

Authors:  M A G J ten Dam; L B Hilbrands; J F M Wetzels
Journal:  Med Oncol       Date:  2010-09-24       Impact factor: 3.064

5.  [The osteoporosis patient with renal insufficiency: what has to be taken into account in the selection and administration of antiosteoporosis medication?].

Authors:  G Lehmann; G Hein; G Wolf
Journal:  Z Rheumatol       Date:  2006-09       Impact factor: 1.372

Review 6.  Targeting the bone microenvironment in multiple myeloma.

Authors:  G David Roodman
Journal:  J Bone Miner Metab       Date:  2010-02-04       Impact factor: 2.626

7.  Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study.

Authors:  Danielle E Robinson; M Sanni Ali; Victoria Y Strauss; Leena Elhussein; Bo Abrahamsen; Nigel K Arden; Yoav Ben-Shlomo; Fergus Caskey; Cyrus Cooper; Daniel Dedman; Antonella Delmestri; Andrew Judge; Muhammad Kassim Javaid; Daniel Prieto-Alhambra
Journal:  Health Technol Assess       Date:  2021-03       Impact factor: 4.014

8.  Safe and tolerable one-hour pamidronate infusion for multiple myeloma patients.

Authors:  Dimitrios Chantzichristos; Björn Andréasson; Peter Johansson
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.